BioSpace News Archive

The new name has been chosen to better reflect the Company’s new strategic focus on applying artificial intelligence to precision medicine and drug discovery and marks a new chapter of the Company’s growth.

During National Thyroid Awareness Month in January, Veracyte, Inc. announced that to date it has performed 100,000 Afirma genomic tests to help reduce unnecessary surgeries in patients being evaluated for potential thyroid cancer.

The data showed that the ADAPT technique was non-inferior to stent retrievers for treatment of large vessel occlusions: 52 percent of patients treated with Penumbra’s aspiration system achieved the primary endpoint of modified Rankin Score (mRS) 0-2 at 90 days compared with 49 percent of patients treated with stent retrievers.

Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health.

Onxeo today announced having received a communication from the European Patent Office (EPO) informing the Company of its intent to grant a new patent covering AsiDNA, Onxeo’s first-in-class DNA break repair inhibitor candidate in all countries of the European Union (EU).

Omnicell will hold a conference call on Thursday, February 1, 2018, to discuss the Company’s Fourth Quarter 2017 financial results.

CTI BioPharma today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI’s common stock from the Borsa Italiana MTA exchange.

Biolase responded to the latest attempt by CAO Group to use patent litigation to try to improve its competitive position in the marketplace.

Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13th, before the market opens.

Developed at the University of Wisconsin-Madison by Drs. Mark Cook and Jordan Sand, this unique innovation targets anti-nutritional challenges found in an animal’s gut.